Form HLTH5476 Special Authority Request - Velpatasvir Plus Sofosbuvir With or Without Ribavirin (Rbv) for Chronic Hepatitis C - British Columbia, Canada

Form HLTH5476 is used in British Columbia, Canada to request special authority for the prescription medication Velpatasvir Plus Sofosbuvir, which is used to treat chronic hepatitis C. This form may also include the option to request Ribavirin as an additional medication.

In British Columbia, Canada, the form HLTH5476 Special Authority Request - Velpatasvir Plus Sofosbuvir With or Without Ribavirin (Rbv) for Chronic Hepatitis C is usually filed by healthcare professionals or physicians on behalf of their patients.

Form HLTH5476 Special Authority Request - Velpatasvir Plus Sofosbuvir With or Without Ribavirin (Rbv) for Chronic Hepatitis C - British Columbia, Canada - Frequently Asked Questions (FAQ)

Q: What is the purpose of the form HLTH5476? A: The purpose of form HLTH5476 is to request Special Authority for Velpatasvir Plus Sofosbuvir With or Without Ribavirin (Rbv) for Chronic Hepatitis C treatment in British Columbia, Canada.

Q: What is Special Authority? A: Special Authority is a process that allows the coverage of specific medications or treatments that are not normally covered under the regular benefits of the British Columbia Medical Services Plan (MSP).

Q: What is Velpatasvir Plus Sofosbuvir? A: Velpatasvir Plus Sofosbuvir is a combination treatment used for Chronic Hepatitis C. It contains two antiviral medications, Velpatasvir and Sofosbuvir, which work together to treat the infection.

Q: Is Ribavirin (Rbv) included in the treatment? A: Ribavirin (Rbv) may or may not be included in the treatment, depending on the specific case and the medical provider's recommendation.

Q: Who is eligible for Special Authority Request? A: Patients with Chronic Hepatitis C who meet specific criteria and have a valid prescription from a healthcare provider are eligible to submit a Special Authority Request.